A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

Summary

This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.

Timeline

Start

2021-11-02

Primary completion

2022-11-28

Completion

2022-11-28

Outcome

Outcome not reported

Stopped (Enrollment): “Due to enrollment challenges”

Drugs

Indications